

ASX Release

**Annual General Meeting
Chairman's Address**

I would like to formally welcome you to your company AGM today and thank you for your ongoing support. Before moving on to the resolutions, I would like to take a moment to reflect on a year that has seen challenges and opportunities for your Company.

During the year, the Company achieved significant milestones including:

- TALI Train being granted Class 2 medical device certification with the Food and Drug Administration (September 2018);
- The first sales of TALI Train commenced to schools in the USA further expanding the market validation activities by the Company; and
- And in June 2019 the Company agreed with the Victorian Education Department to release TALI Detect to all Victorian public-school children in prep, year 1 and year 2.

The year delivered initial sales of the TALI Train product and also identified that the finalisation of the TALI Detect product development (in pre-market release now and full market release in 2020) was critical to ensure long term customer acquisition and global growth.

This primary market feedback has also allowed us to focus on three core areas of healthcare, education and direct to consumer to ensure the most effective widespread adoption of the applications. During the 2020 financial year the focus of the Company is on execution of the “go to market” phase.

TALi (both Train and Detect) are at the forefront of the global digital health and education revolution in the early childhood segment. As both products are software application based, they present a unique opportunity for Novita and global partners we may work with to seamlessly provide additional value add to customers in the education and healthcare segments. As such, the Company intends to execute on a combination of strategic partnerships in the education and healthcare segments with organisations that have direct access to schools and large clinical communities. This will ensure the greatest number of children benefit from these ground-breaking scientific and clinically validated technologies.

Subsequent to the financial year of 2018/2019, and during October and November 2019, the Company has made the following significant announcements which will contribute to the growth objectives of the Company:

- Access to reimbursement CPT Codes for the TALi platform; and
- A private placement that has raised \$AUD6.2m

Our Managing Director will provide further context on how these announcements will assist the Company objectives.

I thank you again, our shareholders, for your support and shared belief in the Company. Thanks also to my fellow Directors for the discipline applied to guiding the Company during the year, and I look forward to keeping shareholders updated as we take our TALi products to market.

Thank you, Ladies and Gentlemen.